Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on February 7, 2017, to report an amendment to its Credit Agreement, dated February 2, 2017. This amendment is primarily related to the company's planned acquisition of its corporate headquarters and related facilities, a transaction previously disclosed in December 2016. The key update is that the financing for this acquisition, specifically lease financing and other similar arrangements, will not be classified as 'Indebtedness' or 'Capital Lease Obligations' under the existing Credit Agreement. This reclassification is significant for investors as it impacts the calculation of Regeneron's total leverage ratio. By excluding this lease financing from debt calculations, the company maintains flexibility within its debt covenants and may present a more favorable leverage profile. Importantly, as of the filing date, no amounts were outstanding under the Credit Agreement, suggesting this amendment is proactive in anticipation of the facility acquisition and its associated financing.
Key Highlights
- 1Regeneron amended its Credit Agreement on February 2, 2017, via Consent and Amendment No. 1.
- 2The amendment addresses the financing for the acquisition of the company's corporate headquarters and related facilities, previously reported in December 2016.
- 3Key provision: Lease financing and similar arrangements for the acquired facility will not be considered 'Indebtedness' or 'Capital Lease Obligations' under the Credit Agreement.
- 4This exclusion impacts the calculation of Regeneron's total leverage ratio.
- 5The amendment aims to provide flexibility within the company's debt covenants.
- 6No amounts were outstanding under the Credit Agreement as of the filing date (February 7, 2017).